MedTrace Pharma announced the first person scanned in its Rapid-Water-Flow Phase 3 clinical trial, further testing its tech to bring 15 O-water to imaging.
The first subject scan took place at Aarhus University Hospital in Denmark, using 15 O-water produced, dosed and injected through MedTrace’s P3 automated delivery system. The clinical trial aims to evaluate the use of 15 O-water in PET scans to diagnose coronary artery disease. The trial kickoff, announced on May 20, comes about two months after MedTrace received FDA approval of the company’s Investigational New Drug (IND) application and the approval to commence the trial.
Denmark–based MedTrace is holding a grand opening in August for new U.S. offices in the IDS Center in downtown Minneapolis.
Read the full story on our sister site Medical Design & Outsourcing.